Skip to main content

Advertisement

SpringerLink
Log in

Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Osteoporosis (OP) is one of the signs of bone damage in rheumatoid arthritis (RA). The 14-3-3η protein is an inflammatory protein, which has been reported to be associated with rheumatoid arthritis (RA). This is to determine the serum levels of 14-3-3η protein, evaluate its diagnostic value in early RA, and clear out its significance in RA with secondary osteoporosis. Two hundred fifty-nine RA patients and 80 age and sex-matched healthy controls were included. Assays of serum 14-3-3η protein were done for all participants by enzyme-linked immunosorbent assay (ELISA). Dual-energy X-ray absorptiometry (DEXA) was used to measure bone mineral density (BMD). Serum 14-3-3η protein level was significantly high in RA (2.49/4.72), compared with controls (P < 0.0001). Positive rate of 14-3-3η protein in RA was 97.3%, which was higher than that in controls (χ 2 = 276.641, P < 0.0001). Serum 14-3-3η protein level in early RA was significantly higher than that in established RA (3.91/4.82 vs 2.01/3.29, Z = 2.624, P < 0.05). The positive rate among three groups (normal control, early RA group, established RA group) differed from each other (χ 2 = 131.396, P < 0.0001). Results of ROC curve indicated the cutoff point of 14-3-3η protein for diagnosis of early RA was 0.879 ng/ml (P < 0.0001). Linear correlation analysis found that serum 14-3-3η protein positively correlated with VAS and HAQ (P < 0.0001), negatively correlated with BMD at lumbar spine and femur in RA (P < 0.0001). Serum 14-3-3η protein among groups of bone mass normal (2.73/3.79), osteopenia (3.15/4.86), and osteoporosis (6.34/6.42) was different in early RA patients (χ 2 = 7.974, P < 0.05). Serum 14-3-3η protein levels increase significantly in patients with RA (especially in early RA). There are close relationships between serum 14-3-3η protein and clinical symptoms and osteoporosis in patients with RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kilani RT, Maksymowych WP, Aitken A, Boire G, St-Pierre Y, Li Y et al (2007) Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation. J Rheumatol 34(8):1650–1657

    CAS  PubMed  Google Scholar 

  2. de Launay LD, van de Sande MG, de Hair MJ, Grabiec AM, van de Sande GP, Lehmann KA et al (2012) Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Ann Rheum Dis 71(3):415–423

    Article  PubMed  Google Scholar 

  3. Yan L, Gu H, Li J, Xu M, Liu T, Shen Y et al (2013) RKIP and 14-3-3ε exert an opposite effect on human gastric cancer cells SGC7901 by regulating the ERK/MAPK pathway differently. Dig Dis Sci 58(2):389–396

    Article  CAS  PubMed  Google Scholar 

  4. Di WT, Vergara F, Bertiller E, Gallardo Mde L, Gandino I, Scolnik M et al (2016) Incidence and prevalence of rheumatoid arthritis in a health management organization in Argentina: a 15-year study. J Rheumatol 43(7):1306–1311

    Article  PubMed  Google Scholar 

  5. Maksymowych WP, Marotta A (2014) 14-3-3eta: a novel biomarker platform for rheumatoid arthritis. Clin Exp Rheumatol 32(2):35–39

    Google Scholar 

  6. Maksymowych WP, Landewé R, Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ et al (2009) Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 36(8):1785–1791

    Article  PubMed  Google Scholar 

  7. Boire G, Carrier N, Brum-fernandes AJ, Liang P, Masetto A, Gui Y et al (2014) 14-3-3ETA predicts radiographic progression in recent-onset polyarthritis patients. Annual of the rheumatic diseases the EULAR. Journal 73(2):603–604

    Google Scholar 

  8. Scott DL, Symmons DP, Coulton BL, Popert AJ (1987) Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1(8542):1108–1011

    Article  CAS  PubMed  Google Scholar 

  9. de Launay D, van de Sande MG, de Hair MJ, Grabiec AM, van de Sande GP, Lehmann KA et al (2012) Selective involvement of ERK and JNK mitogenactivated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. Arthritis Rheum 71(3):415–423

    Google Scholar 

  10. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO et al (2010) 2010 rheumatoid arthritis classification criteria. Arthritis Rheum 62(9):2569–2581

    Article  PubMed  Google Scholar 

  11. Terao C, Hashimoto M, Yamamoto K, Murakami K, Ohmura K, Nakashima R et al (2013) Three groups in the 28 joints for rheumatoid arthritis synovitis—analysis using more than 17,000 assessments in the KURAMA database. PLoS One 8(3):341–349

    Article  Google Scholar 

  12. Kirwan JR, Reeback JS (1986) Stanford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 25:206–209

    Article  CAS  PubMed  Google Scholar 

  13. Seymour RA, Simpson JM, Charlton JE, Phillips ME (1985) An evaluation of length and end-phrase of visual analogue scales in dental pain. Pain 21(2):177–185

    Article  CAS  PubMed  Google Scholar 

  14. AM R, Coleman NW, Knight TA, Belkoff SM, Mears SC (2010) Bone density and cortical thickness in normal, osteopenic, and osteoporotic sacra. J Osteoporos 4(9):123–125

    Google Scholar 

  15. Shi J, van de Stadt LA, Levarht EW, Huizinga TW, Toes RE, Trouw LA et al (2013) Anti-carbamylatedprotein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum 65(4):911–915

    Article  CAS  PubMed  Google Scholar 

  16. Marotta A, Bykerk V, Siminovitch KA, Boers M, Landewé R, van der Heijde D et al (2011) Extracellular 14-3-3: an early rheumatoid arthritis pathogenic factor. Arthritis Rheum 63(10):378–383

    Google Scholar 

  17. Kadavath S, Chittalae S, Nidal shuaib O, Soon GK, Tosic M, Giles J et al (2014) 14-3-3ETA protein: a novel biomarker for the diagnosis of rheumatoid arthritis. Ann Rheum Dis 73(2):666–667

    Google Scholar 

  18. Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D, Boers M et al (2014) Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol 42(11):2104–2113

    Article  Google Scholar 

  19. Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M et al (2015) 14-3-3η autoantibodies: diagnostic use in early rheumatoid arthritis. J Rheumatol 42(9):1587–1594

    Article  CAS  PubMed  Google Scholar 

  20. van Beers-Tas MH, Marotta A, Boers M, Maksymowych WP, van Schaardenburg D (2016) A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia. Arthritis Res Ther 18:1176–1189

    Google Scholar 

  21. Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y (2015) Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther 17(1):1–10

    Article  Google Scholar 

  22. Cockrell LM, Puckett MC, Goldman EH, Khuri FR, Fu H (2010) Dual engagement of 14-3-3 proteins controls signal relay from ASK2 to the ASK1 signalosome. Oncogene 29(6):822–830

    Article  CAS  PubMed  Google Scholar 

  23. Van Schaardenburg V, Maksymowych WP, Marotta A (2014) Lower levels of 14-3-3ETA predict DEMARD associated DAS remission at 1 year follow up. Annual of the rheumatic diseases the EULAR. Journal 73:38

    Google Scholar 

  24. Baillet A, Gossec L, Paternotte S, Etcheto A, Combe B, Meyer O et al (2015) Evaluation of serum interleukin-6 level as a surrogate marker of synovial inflammation and as a factor of structural progression in early rheumatoid arthritis: results from a French national multicenter cohort. Arthritis Care Res 67(7):905–912

    Article  CAS  Google Scholar 

  25. Maksymowych WP, van der Heijde D, Allaart CF, Landewé R, Boire G, Tak PP et al (2014) 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther 16(2):R99

    Article  PubMed  PubMed Central  Google Scholar 

  26. Yaffe MB (2002) How do 14-3-3 proteins work? Gatekeeper phosphorylationand the molecular anvil hypothesis. FEBS Lett 513(1):53–57

    Article  CAS  PubMed  Google Scholar 

  27. van Beers-Tas MH, Marotta A, Boers M, Maksymowych WP, van Schaardenburg D (2016) A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia. Arthritis Res Ther 18(1):76–87

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank all the individuals who have helped us in this study.

Funding

The study was supported by grants from the National Natural Science Foundation of China (81571572)

Author information

Authors and Affiliations

  1. Department of Rheumatology & Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

    Xun Gong, Sheng-qian Xu, Ying Wu, Can-chen Ma, Shan Qi, Wen Liu & Jian-hua Xu

Authors
  1. Xun Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sheng-qian Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Can-chen Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shan Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian-hua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheng-qian Xu.

Ethics declarations

Disclosures

None.

Publisher’s disclaimer

The work described has not been published before; that it is not under consideration for publication anywhere else; and that its publication has been approved by all co-authors, if any, as well as by the responsible authorities—tacitly or explicitly—at the institute where the work has been carried out. The publisher will not be held legally responsible should there be any claims for compensation.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gong, X., Xu, Sq., Wu, Y. et al. Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population. Clin Rheumatol 36, 2581–2587 (2017). https://doi.org/10.1007/s10067-017-3807-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3807-2

Keywords

Search

Navigation